TRACON Pharmaceuticals, Inc.
(NASDAQ : TCON)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.34%178.120.7%$1344.93m
MRKMerck & Co., Inc. 0.55%91.670.7%$1174.23m
PFEPfizer Inc. -1.08%51.870.9%$1101.79m
LLYEli Lilly & Co. -0.91%321.271.1%$1036.13m
BMYBristol-Myers Squibb Co. -1.00%76.231.0%$997.78m
ABBVAbbVie, Inc. -0.59%152.251.9%$953.03m
AZNAstraZeneca Plc -1.00%65.411.0%$437.07m
SGENSeagen Inc. 0.90%178.545.7%$318.75m
TPTXTurning Point Therapeutics, Inc. -0.12%75.160.0%$287.74m
GSKGSK Plc -0.15%43.470.2%$276.07m
HZNPHorizon Therapeutics Plc 1.04%80.595.4%$163.49m
NVSNovartis AG -0.91%83.760.2%$163.07m
MRTXMirati Therapeutics, Inc. 2.96%69.121.6%$151.06m
NVONovo Nordisk A/S -0.54%110.830.1%$142.45m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.17%145.470.0%$142.09m

Company Profile

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.